Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 381

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 381
---
 Early adoption is permitted. The Company’s management does not believe the
adoption of ASU 2023-09 will have a material impact on its consolidated financial statements and disclosures.

Management does not believe that any other recently
issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed
financial statements.

Note 3 — Initial Public Offering and Over-Allotment

Pursuant to the IPO, the Company sold 17,500,000
units (including 2,000,000 units as part of the underwriter’s partial exercise of the over-allotment option) at a price of $10.00
per Unit. Each Unit consists of one Public Share, and a Public Warrant. Each Public Warrant entitles the holder to purchase one share
of Class A common stock at a price of $11.50 per share, subject to adjustment (see Note 7).

Note 4 — Private Placement Warrants

On October 8, 2021, simultaneously with the
consummation of the IPO, the Company consummated the issuance and sale (“Private Placement”) of the Private Placement Units
in a private placement transaction at a price of $10.00 per Private Placement Unit, generating gross proceeds of $8,850,000. The Private
Placement Units were purchased by Cantor (155,000 Units), CCM (30,004 Units) and the Sponsor (699,996 Units). Each whole Private
Placement Unit consists of one Private Placement Share and one-half of a redeemable warrant (“Private Placement Warrant”).
Each whole Private Placement Warrant will be exercisable to purchase one share of Class A common stock at a price of $11.50
per share, subject to adjustment. A portion of the proceeds from the Private Placement Units was added to the proceeds from the IPO to
be held in the Trust Account. If the Company does not complete a business combination within the Combination Period, the proceeds from
the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable
law), and the Private Placement Units and all underlying securities will be worthless.

<div align='center'>F-40

PHOENIX BIOTECH ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2023</div>

Note 5 — Related Party Transactions

Founder Shares

On September